press release: Pfizer Licenses PARP Inhibitor To Clovis Oncology (PF-01367338) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, June 02, 2011

press release: Pfizer Licenses PARP Inhibitor To Clovis Oncology (PF-01367338)



"...PF-01367338 would be developed by Clovis as both a monotherapy and in combination with chemotherapeutic agents for the potential treatment of selected cancer patients.
PF-01367338 is currently in a Phase 1 clinical trial examining the maximum tolerated dose of oral PF-01367338 that can be combined with intravenous platinum chemotherapy in the treatment of solid tumors.
Supplementing this trial are two ongoing trials, currently using the IV formulation, a Phase 1/2 study in germline BRCA-mutant (gBRCA) breast and ovarian cancer and a Phase 2 study in the adjuvant treatment of triple negative breast cancer. Clovis intends to replace the IV formulation with the oral formulation in these studies.
Clovis was founded by former executives of Pharmion Corp., which was acquired by Celgene Corporation in 2008. The company is headquartered in Boulder, Colorado, and has additional offices in San Francisco and London."

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.